James E Galvin

NIH Rank #170

NIH Funding · FY2024

Total Funding

$15.4M

Fiscal year 2024

Grants Awarded

Active NIH grants

National Rank

#170

Among 57,894 PIs

First NIH Award

2024

Year of first funding

NIH funding totals and national rank by fiscal year.

Single fiscal year on record (FY2024): $15.4M across 8 grants · National rank #170.

James E Galvin's NIH grant portfolio, ranked by award amount.

5R01AG080536-02R01
A Phase 2b Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients with Mild-to-Moderate Dementia with Lewy Bodies (DLB)
Eip Pharma, Inc.
$8.1M
award amount
5R01AG071514-04R01
Multicultural Community Dementia Screening
University of Miami School of Medicine
$2.6M
award amount
1U01AG084528-01U01
IND enabling CMC/safety/toxicology studies, submission of IND and pilot Phase 1 clinical trial with PV-1950R vaccine for Lewy Body Dementia (LBD)
Institute for Molecular Medicine
$1.8M
award amount
5R01AG057681-05R01
The LUCINDA Trial
Weill Cornell Medicine
$1.4M
award amount
5R01AG069765-05R01
Digital Detection of Dementia Studies (D cubed Studies).
Indiana University Indianapolis
$939.3K
award amount
1T32AG081170-01A1T32
Cross-disciplinary research opportunity for training in AD/ADRD science (CROSSROADS)
University of Miami School of Medicine
$277.7K
award amount
3R01AG080536-02S1R01
A Phase 2b Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients with Mild-to-Moderate Dementia with Lewy Bodies (DLB)
Eip Pharma, Inc.
$250K
award amount
5P30AG059295-07P30
Native Alzheimer Disease Resource Center for Minority Aging Research (NAD-RCMAR)
University of Miami School of Medicine
$62.1K
award amount